EE398 Cost Comparison of Osimertinib Plus Chemotherapy Versus Amivantamab Plus Lazertinib for the First-Line Treatment of Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC
Jul 1, 2025, 00:00
10.1016/j.jval.2025.04.1997
https://www.valueinhealthjournal.com/article/S1098-3015(25)02126-6/fulltext
Title :
EE398 Cost Comparison of Osimertinib Plus Chemotherapy Versus Amivantamab Plus Lazertinib for the First-Line Treatment of Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)02126-6&doi=10.1016/j.jval.2025.04.1997
First page :
Section Title :
Open access? :
No
Section Order :
10174